Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone versus eplerenone in chronic heart failure with reduced ejection fraction after recent decompensation
2015-002168-17Phase 3Terminated
- Sponsor
- Bayer
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of finerenone in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Bayer. Primary endpoint: Time to first occurrence of the primary composite endpoint. Started Sep 2015; status: terminated.
02
Drugs
finerenone
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2015-002168-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002168-17.